Skip to main content

Advertisement

SpringerLink
Log in

Animal models of multiple sclerosis for the development and validation of novel therapies – potential and limitations

  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Various types of experimental autoimmune encephalomyelitis (EAE) reflect some of the pathogenetic, clinical, and therapeutic features of the different forms of multiple sclerosis (MS), thereby, providing some, albeit limited, insight into the molecular and cellular basis of the human disease. Specific questions of MS therapy including the search for new therapeutic targets and strategies and their validation require investigations in different available EAE models. A survey is given of experimental therapeutic approaches that are currently under study with the most promising examples of monoclonal antibodies, gene therapy, stem cell transplantation and orally applied small molecular weight disease-modifying drugs. Reasons for therapy failure and adverse side-effects of some experimental trials are discussed. Precaution is advised, if results of new experimental approaches are translated into clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952:128–134

    Article  PubMed  CAS  Google Scholar 

  2. Aharoni R, Teitelbaum D, Sela M, Arnon R (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 94:10821–10826

    Article  PubMed  CAS  Google Scholar 

  3. Aharoni R, Herschkovitz A, Eilam R, Blumberg-Hazan M, Sela M, Brück W, Arnon R (2008) Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 105:11358–11363

    Article  PubMed  CAS  Google Scholar 

  4. Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T (2008) Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS ONE 3:e3145 (1–10)

    Article  PubMed  CAS  Google Scholar 

  5. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197:725–733

    Article  PubMed  CAS  Google Scholar 

  6. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 173:5794–5800

    PubMed  CAS  Google Scholar 

  7. Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, Foster CA (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74:307–316

    Article  PubMed  CAS  Google Scholar 

  8. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 118:1532–1543

    Article  PubMed  CAS  Google Scholar 

  9. Bechtold DA, Kapoor R, Smith KJ (2004) Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607–616

    Article  PubMed  CAS  Google Scholar 

  10. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, Smith KJ (2006) Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 253:1542–1551

    Article  PubMed  Google Scholar 

  11. Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Béraud E (2001) Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 166:936–944

    PubMed  CAS  Google Scholar 

  12. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167–1175

    Article  PubMed  CAS  Google Scholar 

  13. Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG (2007) Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 62:21–33

    Article  PubMed  CAS  Google Scholar 

  14. Broberg EK, Salmi AA, Hukkanen V (2004) IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis. Neurosci Lett 364:173–178

    Article  PubMed  CAS  Google Scholar 

  15. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125:1297–1308

    Article  PubMed  Google Scholar 

  16. Butti E, Bergami A, Recchia A, Brambilla E, Del Carro U, Amadio S, Cattalini A, Esposito M, Stornaiuolo A, Comi G, Pluchino S, Mavilio F, Martino G, Furlan R (2008) IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther 15:504–1515

    Article  PubMed  CAS  Google Scholar 

  17. Buttmann M, Rieckmann P (2008) Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 8:433–455

    Article  PubMed  CAS  Google Scholar 

  18. Carlson RP, Baeder WL, Caccese RG, Warner LM, Sehgal SN (1993) Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann N Y Acad Sci 685:86–113

    Article  PubMed  CAS  Google Scholar 

  19. Cohen BA, Rieckmann P (2007) Emerging oral therapies for multiple sclerosis. Int J Clin Pract 61:1922–1930

    Article  PubMed  CAS  Google Scholar 

  20. Correale J, Farez M, Gilmore W (2008) Vaccines for multiple sclerosis: progress to date. CNS Drugs 22:175–198

    Article  PubMed  CAS  Google Scholar 

  21. Diem R, Sättler MB, Merkler D, Demmer I, Maier K, Stadelmann C, Ehrenreich H, Bähr M (2005) Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128:375–385

    Article  PubMed  Google Scholar 

  22. Dimitriadou V, Pang X, Theoharides TC (2000) Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation. Int J Immunopharmacol 22:673–684

    Article  PubMed  CAS  Google Scholar 

  23. Dittrich F, Thoenen H, Sendtner M (1994) Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann Neurol 35:151–163

    Article  PubMed  CAS  Google Scholar 

  24. Einstein O, Grigoriadis N, Mizrachi-Kol R, Reinhartz E, Polyzoidou E, Lavon I, Milonas I, Karussis D, Abramsky O, Ben-Hur T (2006) Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp Neurol 198:275–284

    Article  PubMed  CAS  Google Scholar 

  25. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111:715–722

    Article  PubMed  CAS  Google Scholar 

  26. Espejo C, Penkowa M, Demestre M, Montalban X, Martínez-Cáceres EM (2005) Time-course expression of CNS inflammatory, neurodegenerative tissue repair markers and metallothioneins during experimental autoimmune encephalomyelitis. Neuroscience 132:1135–1349

    Article  PubMed  CAS  Google Scholar 

  27. Faria AM, Weiner HL (2006) Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 13:143–157

    Article  PubMed  CAS  Google Scholar 

  28. Foley TT, Hentosh P, Walters DE (2004) 2-Chloro-2’-deoxyadenosine: alteration of DNA:TATA element binding protein (TBP) interactions. J Mol Model 10:32–37

    Article  PubMed  CAS  Google Scholar 

  29. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, Sobanov J, Kinnunen A, Baumruker T (2008) FTY720 rescue therapy in the Dark Agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 2008 Jun 4 [Epub ahead of print]

  30. Furlan R, Pluchino S, Martino G (2003) Gene therapy-mediated modulation of immune processes in the central nervous system. Curr Pharm Des 9:2002–2008

    Article  PubMed  CAS  Google Scholar 

  31. Garay L, Gonzalez Deniselle MC, Gierman L, Meyer M, Lima A, Roig P, De Nicola AF (2008) Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation 15:76–83

    PubMed  CAS  Google Scholar 

  32. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953–1971

    Article  PubMed  Google Scholar 

  33. Hassen GW, Feliberti J, Kesner L, Stracher A, Mokhtarian F (2008) Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. Brain Res 1236:206–215

    Article  PubMed  CAS  Google Scholar 

  34. Hendriks JJ, Alblas J, van der Pol SM, van Tol EA, Dijkstra CD, de Vries HE (2004) Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 200:1667–1672

    Article  PubMed  CAS  Google Scholar 

  35. Hünig T (2007) Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 95:111–148

    Article  PubMed  CAS  Google Scholar 

  36. Jones JL, Coles AJ (2008) Campath-1H treatment of multiple sclerosis. Neurodegener Dis 5:27–31

    Article  PubMed  CAS  Google Scholar 

  37. Jørgensen SH, Storm N, Jensen PE, Laursen H, Sørensen PS (2007) IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp Brain Res 178:462–469

    Article  PubMed  CAS  Google Scholar 

  38. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6:1176–1182

    Article  PubMed  CAS  Google Scholar 

  39. Karpus WJ, Reynolds N, Behanna HA, Van Eldik LJ, Watterson DM (2008) Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. J Neuroimmunol 203:73–78

    Article  PubMed  CAS  Google Scholar 

  40. Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A (2007) Rapamycin enriches for CD4+CD25+CD27+Foxp3+ regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 9:144–157

    Article  PubMed  CAS  Google Scholar 

  41. Kieseier BC, Wiendl H (2007) Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 21:483–502

    Article  PubMed  CAS  Google Scholar 

  42. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374

    Article  PubMed  CAS  Google Scholar 

  43. Kobayashi N, Kiptoo P, Kobayashi H, Ridwan R, Brocke S, Siahaan TJ (2008) Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin Immunol 129:69–79

    Article  PubMed  CAS  Google Scholar 

  44. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381

    Article  PubMed  CAS  Google Scholar 

  45. Lavi E, Constantinescu CS (eds) (2005) Experimental models of multiple sclerosis. Springer, New York

  46. Lindsey JW (2005) EAE: history, clinical signs, and disease course. In: Lavi E, Constantinescu CS (eds) Experimental models of multiple sclerosis. Springer, New York, pp 1–9

  47. Linker RA, Weller C, Lühder F, Mohr A, Schmidt J, Knauth M, Metselaar JM, Gold R (2008a) Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol 211:397–406

    Article  PubMed  CAS  Google Scholar 

  48. Linker RA, Kieseier BC, Gold R (2008b) Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 29:558–565

    Article  PubMed  CAS  Google Scholar 

  49. Lipton MM, Freund J (1952) Encephalomyelitis in the rat following intracutaneous injection of central nervous system tissue with adjuvant. Proc Soc Exp Biol Med 81:260–261

    PubMed  CAS  Google Scholar 

  50. Lo AC, Saab CY, Black JA, Waxman SG (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90:3566–3571

    Article  PubMed  CAS  Google Scholar 

  51. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK (2004) Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease. J Immunol 172:5790–5798

    PubMed  CAS  Google Scholar 

  52. Lutterotti A, Martin R (2008) Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 7:538–547

    Article  PubMed  CAS  Google Scholar 

  53. Makar TK, Trisler D, Bever CT, Goolsby JE, Sura KT, Balasubramanian S, Sultana S, Patel N, Ford D, Singh IS, Gupta A, Valenzuela RM, Dhib-Jalbut S (2008a) Stem cell based delivery of IFN-β reduces relapses in experimental autoimmune encephalomyelitis. J Neuroimmunol 196:67–81

    Article  PubMed  CAS  Google Scholar 

  54. Makar TK, Trisler D, Sura KT, Sultana S, Patel N, Bever CT (2008b) Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J Neurol Sci 270:70–76

    Article  PubMed  CAS  Google Scholar 

  55. Martino G, Pluchino S (2007) Neural stem cells: guardians of the brain. Nat Cell Biol 9:1031–1034

    Article  PubMed  CAS  Google Scholar 

  56. McLaughlin KA, Wucherpfennig KW (2008) B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 98:121–149

    Article  PubMed  CAS  Google Scholar 

  57. Melzer N, Meuth SG, Torres-Salazar D, Bittner S, Zozulya AL, Weidenfeller C, Kotsiari A, Stangel M, Fahlke C, Wiendl H (2008) A β-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS ONE 3:e3149 (1–12)

    Article  PubMed  CAS  Google Scholar 

  58. Meuth SG, Bittner S, Meuth P, Simon OJ, Budde T, Wiendl H (2008) TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J Biol Chem 283:14559–14570

    Article  PubMed  CAS  Google Scholar 

  59. Miron VE, Schubart A, Antel JP (2008) Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274:13–17

    Article  PubMed  CAS  Google Scholar 

  60. Mirowska-Guzel D (2008) The role of neurotrophic factors in the pathology and treatment of multiple sclerosis. Immunopharmacol Immunotoxicol. 2008 Sep 15:1–14 [Epub ahead of print]

    Google Scholar 

  61. Mix E, Ibrahim SM, Pahnke J, Glass A, Mazón-Peláez I, Lemcke S, Koczan D, Gimsa U, Bansemer S, Scheel T, Karopka T, Böttcher T, Müller J, Dazert E, Antipova V, Hoffrogge R, Wree A, Zschiesche M, Strauss U, Kundt G, Warzok R, Gierl L, Rolfs A (2006) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE. J Autoimmun 27:251–265

    Article  PubMed  CAS  Google Scholar 

  62. Morgan IM (1947) Allergic encephalomyelitis in monkeys in response to injection of normal monkey nervous tissue. J Exp Med 85:131–140

    Article  Google Scholar 

  63. Morrissey SP, Stodal H, Zettl U, Simonis C, Jung S, Kiefer R, Lassmann H, Hartung HP, Haase A, Toyka KV (1996) In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain 119:239–248

    Article  PubMed  Google Scholar 

  64. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S (2008) Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 373:286–291

    Article  CAS  Google Scholar 

  65. Nath N, Giri S, Prasad R, Salem ML, Singh AK, Singh I (2005) 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol 175:566–574

    PubMed  CAS  Google Scholar 

  66. Noseworthy JH, O’Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, Rice GP, Auty A, Hader WJ, Kirk A, Duquette P, Carter J, Francis G, Metz L, Shuster E (1998) The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51:1342–1352

    PubMed  CAS  Google Scholar 

  67. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54:1726–1733

    PubMed  CAS  Google Scholar 

  68. O’Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894–900

    Article  PubMed  CAS  Google Scholar 

  69. Olitzky PK, Yager RH (1949) Experimental disseminated encephalomyelitis in white mice. J Exp Med 90:213–224

    Article  Google Scholar 

  70. Olsson T, Dahlman I, Wallström E, Weissert R, Piehl F (2000) Genetics of rat neuroinflammation. J Neuroimmunol 107:191–200

    Article  PubMed  CAS  Google Scholar 

  71. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O’Connor KC, Hafler DA, Sobel RA, Robinson WH, Steinman L (2007) Protective and therapeutic role for αB-crystallin in autoimmune demyelination. Nature 448:474–479

    Article  PubMed  CAS  Google Scholar 

  72. Paintlia AS, Paintlia MK, Singh I, Singh AK (2006) Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 169:1012–1025

    Article  PubMed  CAS  Google Scholar 

  73. Paintlia AS, Paintlia MK, Singh I, Singh AK (2008) Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 2008 Aug 7 [Epub ahead of print]

  74. Pedemonte E, Benvenuto F, Casazza S, Mancardi G, Oksenberg JR, Uccelli A, Baranzini SE (2007) The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics 8:65 (1–14)

    Article  PubMed  CAS  Google Scholar 

  75. Pedersen LB, Nashold FE, Spach KM, Hayes CE (2007) 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 85:2480–2490

    Article  PubMed  CAS  Google Scholar 

  76. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310:850–855

    Article  PubMed  CAS  Google Scholar 

  77. Pluchino S, Martino G (2008) The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. J Neurol Sci 265:105–110

    Article  PubMed  CAS  Google Scholar 

  78. Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS (1985) Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 35:35–42

    Article  PubMed  CAS  Google Scholar 

  79. Rieckmann P, Weber F, Günther A, Poser S (1996) The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis. Neurology 47:604

    PubMed  CAS  Google Scholar 

  80. Rieckmann et al. Multiple Sclerosis Therapy Consensus Group (2004) Escalating immunotherapy of multiple sclerosis – new aspects and practical application. J Neurol 251:1329–1339

    Article  PubMed  CAS  Google Scholar 

  81. Rivers TM, Sprunt DH, Berry GP (1933) Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 58:39–53

    Article  Google Scholar 

  82. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69:785–789

    Article  PubMed  CAS  Google Scholar 

  83. Rose JW, Foley J, Carlson N (2008) Monoclonal antibody treatments for multiple sclerosis. Curr Neurol Neurosci Rep 8:419–426

    Article  PubMed  CAS  Google Scholar 

  84. Runström A, Leanderson T, Ohlsson L, Axelsson B (2006) Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 173:69–78

    Article  PubMed  CAS  Google Scholar 

  85. Sättler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bähr M, Diem R (2004) Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 11 (Suppl 2):S181–S192

    Article  PubMed  CAS  Google Scholar 

  86. Schilling S, Goelz S, Linker R, Luehder F, Gold R (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145:101–107

    Article  PubMed  CAS  Google Scholar 

  87. Schmidt J, Gold R, Schönrock L, Zettl UK, Hartung HP, Toyka KV (2000) Tcell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123:1431–1441

    Article  PubMed  Google Scholar 

  88. Scolding (2006) Stem cell therapy in patients with multiple sclerosis. Mult Scler 12:677–678

    Article  PubMed  Google Scholar 

  89. Sipe JC, Romine JS, Koziol JA, Mc-Millan R, Zyroff J, Beutler E (1996) Development of cladribine treatment in multiple sclerosis. Mult Scler 1:343–347

    PubMed  CAS  Google Scholar 

  90. Smith T, Groom A, Zhu B, Turski L (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6:62–66

    Article  PubMed  CAS  Google Scholar 

  91. Stanislaus R, Pahan K, Singh AK, Singh I (1999) Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 269:71–74

    Article  PubMed  CAS  Google Scholar 

  92. Steinman L, Zamvil SS (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12–21

    Article  PubMed  CAS  Google Scholar 

  93. Strauss U, Wissel K, Jung S, Wulff H, Hänsel W, Zhu J, Rolfs A, Mix E (2000) K+ channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis. Immunopharmacology 48:51–63

    Article  PubMed  CAS  Google Scholar 

  94. Stüve O, Bennett JL (2007) Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 13:79–95

    Article  PubMed  Google Scholar 

  95. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1:242–248

    Article  PubMed  CAS  Google Scholar 

  96. van der Meide PH, de Labie MC, Ruuls SR, Groenestein RJ, Botman CA, Olsson T, Dijkstra CD (1998) Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 84:14–23

    Article  PubMed  CAS  Google Scholar 

  97. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531–1534

    PubMed  CAS  Google Scholar 

  98. Waiczies S, Bendix I, Zipp F (2008) Geranylgeranylation but not GTPloading of Rho GTPases determines T cell function. Sci Signal 1:pt3 (1–3)

    Article  PubMed  Google Scholar 

  99. Wang J, Wang G, Sun B, Li H, Mu L, Wang Q, Li G, Shi L, Jin L, Kostulas N (2008) Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 30:222–229

    Article  PubMed  CAS  Google Scholar 

  100. Weber F, Polak T, Günther A, Kubuschok B, Janovskaja J, Bitsch A, Poser S, Rieckmann P (1998) Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 44:27–34

    Article  PubMed  CAS  Google Scholar 

  101. Weishaupt A, Kuhlmann T, Schönrock LM, Toyka KV, Brück W, Gold R (2002) Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol 104:385–390

    PubMed  CAS  Google Scholar 

  102. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16:183–200

    Article  PubMed  CAS  Google Scholar 

  103. Wolf A, Kabat EA, Bezer AE (1947) The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease. J Neuropath Exp Neurol 6:333–357

    Article  Google Scholar 

  104. www.fda.gov/cder/drug/infopage/natalizumab/default.htm

  105. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 156:3–9

    Article  PubMed  CAS  Google Scholar 

  106. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356:63–66

    Article  PubMed  CAS  Google Scholar 

  107. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933

    Article  PubMed  CAS  Google Scholar 

  108. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78–84

    Article  PubMed  CAS  Google Scholar 

  109. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P (2008) Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS ONE 3:e1924 (1–18)

    Article  PubMed  CAS  Google Scholar 

  110. Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Hörl WH, Waldhäusl W, Stulnig TM, Säemann MD (2005) Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52:2730–2739

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Rostock, Dept. of Neurology, Gehlsheimer Str. 20, 18147, Rostock, Germany

    Eilhard Mix, Hans Meyer-Rienecker & Uwe K. Zettl

Authors
  1. Eilhard Mix
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Meyer-Rienecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uwe K. Zettl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eilhard Mix.

Additional information

Conflict of interest Eilhard Mix, Hans Meyer-Rienecker and Uwe K. Zettl have no conflict of interest to declare.

Acknowledgment The authors are most grateful to Gabriele Gillwaldt for providing the art work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mix, E., Meyer-Rienecker, H. & Zettl, U.K. Animal models of multiple sclerosis for the development and validation of novel therapies – potential and limitations. J Neurol 255 (Suppl 6), 7–14 (2008). https://doi.org/10.1007/s00415-008-6003-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-6003-0

Key words

Search

Navigation